| PP100324000179 |
Kubota Pharmaceutical Holdings Co., Ltd. (since 2020), Acucela Inc. |
Retakubo, ACU-4429 |
emixustat hydrochloride |
Visual cyc.. |
Stargardt .. |
Phase III, Phase II completed, Phase II, Preclinical, Preclinical |
View Details
|
| PP090602001253 |
AVEO Oncology, A LG Chem |
AV-299 |
ficlatuzumab |
A high-aff.. |
Squamous c.. |
Phase III, Phase II, Phase II |
View Details
|
| PP081124002334 |
LadRx Corporation (since Sep 2022), CytRx Corporation |
INNO-206, DOXO-EMCH |
aldoxorubicin |
Intercalat.. |
2nd line s.. |
Phase III completed, Phase II, Phase II, Phase II |
View Details
|
| PP100209004495 |
Ligand Pharmaceuticals, Inc. |
FABLYN® |
lasofoxifene |
A nonstero.. |
Osteoporos.. |
Approved, Phase III |
View Details
|
| PP121204010538 |
Larimar Therapeutics, Inc. |
CTI-1601 |
nomlabofusp |
Replacemen.. |
Friedreich.. |
Phase II completed |
View Details
|
| PP130805011737 |
KYORIN Pharmaceutical Co., Ltd. |
KRP-203 |
mocravimod |
A sphingos.. |
Acute myel.. |
Phase III, Phase II, Phase II, Phase II |
View Details
|
| PP131218011954 |
KUMHO HT INC.(since 2021), Dinona Inc. |
DNP001 |
|
Targeting .. |
Acute myel.. |
Phase I completed, Phase I completed |
View Details
|
| PP140318012062 |
AVEO Pharmaceuticals, Inc. |
AV-203, CAN017 |
|
A ErbB3 (H.. |
Esophageal.. |
Phase I completed |
View Details
|
| PP140318012065 |
AVEO Oncology, A LG Chem (since Jan 2023), AVEO Oncology |
AV-380 |
|
An anti-gr.. |
Cachexia |
Phase I |
View Details
|
| PP160713014445 |
KUMHO HT INC.(since 2021), Dinona Inc. |
DNP002 |
|
Enhanced A.. |
Non-small-.. |
Phase I completed, Phase I completed, Phase I completed |
View Details
|